MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

MRNA · NASDAQ-GS

Moderna, Inc.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

Reference price$55.81As of Jul 28, 2026
Market capitalization$22.14B
52-week range$22.28–$85.60
S&P 500 portfolio weight0.03%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$38.00-31.9% vs. reference
Average$48.08-13.8% vs. reference
High$77.00+38.0% vs. reference
1 Buy12 Hold2 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportJul 31, 2026Jun 2026
Consensus EPS-$1.978 estimates
Expected range-$2.35–-$1.32Low to high EPS
Dec 2026-$6.41Street EPS consensus
Dec 2027-$4.33Street EPS consensus
Dec 2028-$1.67Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue-39.9% YoY$1.94B$3.24B
Operating income($3.07B)($3.95B)
Net income($2.82B)($3.56B)
Operating cash flow($1.87B)($3B)
Capital expenditures($0.19B)($1.05B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

The Motley Fool

After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?

The Motley Fool

Moderna: A Stock to Watch or a Risky Bet?

BNK Invest

Friday's ETF with Unusual Volume: FTXH

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.